The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
Open accessAbstract
To assess the clinical significance of lupus anticoagulants (LAs) and antiphospholipid antibodies (aPLs) toward thrombosis and abortions, we measured them in 112 patients whose samples were available at enrollment in the warfarin in the antiphospholipid syndrome (WAPS) study. Enzyme-linked immunosorbent assay (ELISA) and coagulation test values in the highest and lowest tertiles were compared. When considered separately, IgG antibodies to β2-glycoprotein I (aβ2GPI) and prothrombin (aPT) were associated with anamnestic arterial and venous thrombosis, respectively, and those to annexin AV (aAnAV) with abortions. IgM antibodies to protein S and the lupus ratio of the dilute prothrombin time were associated with prospective thrombosis. No other association for IgM antibodies was seen. LA-positive patients who carried aβ2GPI antibodies were at risk of anamnestic arterial and total thrombosis and aPT antibodies to that of anamnestic venous and total thrombosis. LA-positive patients who carried IgG aβ2GPI and aAnAV antibodies were at risk for both anamnestic abortion and prospective thrombosis. Overall, these data support the inclusion of aβ2GPI antibodies in and suggest the removal of anticardiolipin antibodies from the laboratory criteria of the antiphospholipid syndrome. They also suggest that the measurement of aPT and aAnAV antibodies is useful in some selected situations and that there is little role for IgM antibody detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, a considerable proportion of patients with LA will not develop thrombosis despite the presence of aPL-associated autoantibodies at high titers [7].”
From Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While triple positivity has been shown to be a significant thrombotic risk factor in the WAPS study [7], several more recent prospective cohorts have also observed a lack of association between triple positivity or other LA-related autoantibodies and thrombosis [30, 32, 33].”
From Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant (2017) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
McNeil, H. P., Simpson, R. J., Chesterman, C. N., & Krilis, S. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4120 · Cited by 1,595
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
Galli, M., Barbui, T., Comfurius, P., Maassen, C., Hemker, H. C., Zwaal, R. F. A., Bevers, E. M., Baets, M. H. D., & Vriesman, P. J. C. V. B. (1990) · The Lancet · doi:10.1016/0140-6736(90)91374-j · Cited by 1,266
Self-citationBrandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972 · cited 2×
“In 2003, two systematic reviews of the literature on LA, aCL, aβ2GPI and aPT antibodies showed that LA are the strongest risk factors for both arterial and venous thrombosis, whereas such a role did not clearly emerge for the other antibodies, unless in some selected clinical scenarios (10, 11).”
BackgroundResultSelf-citationCrowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035241 · Cited by 919
Harris, E. N., Gharavi, A. E., Patel, S., & Hughes, G. R. (1987) · PubMed Central · Cited by 724
Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
Matsuura, E., Igarashi, Y., Fujimoto, M., Ichikawa, K., & Koike, T. (1990) · The Lancet · doi:10.1016/0140-6736(90)91697-9 · Cited by 718
Research works printed but not linked: 2
- Harris, 1987, Evaluation of the anticardiolipin antbody test: report of a standardization workshop, held April 4th, 1986., Clin Exp Immunol, 68, 215
- Van Heerde, 2004, Localization of annexin A5 in human tissues., Annexins, 1, 56
Cited by
Sorted by citations
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz‐Irastorza, G., & Hughes, G. R. V. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,480
Ruiz‐Irastorza, G., Crowther, M. A., Branch, W. D., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 875
Guidelines on the investigation and management of antiphospholipid syndrome
Keeling, D., Mackie, I., Moore, G. W., Greer, I. A., Greaves, M., & British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09037.x · Cited by 740
Pathogenesis of antiphospholipid syndrome: understanding the antibodies
Meroni, P. L., Borghi, M. O., Raschi, E., & Tedesco, F. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.52 · Cited by 620
Ruiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506
Metadata
- Authors
- Galli, M., Borrelli, G., Jacobsen, E. M., Marfisi, R. M., Finazzi, G., Marchioli, R., Wisloff, F., Marziali, S., Morboeuf, O., & Barbui, T.
- Affiliations
- Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy;
- Mario Negri Sud Foundation (IT)
- Ulleval Hospital, Oslo, Norway;
- Stago (France) (FR)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-08-15
- Volume
- 110
- Issue
- 4
- Pages
- 1178-1183
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2084234423
- Cited by
- 170
- References
- 37
- Citations by year
- 2025: 5 · 2024: 2 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 8 · 2014: 14 · 2013: 7 · 2012: 8
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- antiphospholipid syndrome, antiphospholipid antibodies, lupus anticoagulant, anti-beta2-glycoprotein I antibodies, anticardiolipin antibodies, arterial thrombosis, venous thrombosis, miscarriage, thrombosis risk
- MeSH terms
- Abortion, Habitual, Adult, Aged, Aged, 80 and over, Female, Humans, Immunoglobulin G, Immunoglobulin M, Male, Middle Aged, Pregnancy, Pregnancy Complications, Hematologic, Prospective Studies, Risk Factors, Thromboembolism, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Antibodies, Anticardiolipin, beta 2-Glycoprotein I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
